Is complement a target for therapy in renal disease?  by Mathieson, Peter W.
PERSPECTIVES IN BASIC SCIENCE
Is complement a target for therapy in renal disease?
PETER W. MATHIESON
Academic Renal Unit, University of Bristol, Bristol, England, United Kingdom
Is complement a target for therapy in renal disease? Complement
deposition in the injured kidney is common, especially in glomer-
ulonephritis. The precise role of the complement system in the
mediation of tissue injury in the kidney has been defined in recent
years, and this has assumed extra importance with the recent
development of specific forms of therapy directed at the comple-
ment pathway. As well as the induction of cell lysis, complement
has many subtle effects on cell biology, particularly on endothelial
cells. Complement components are produced locally in the kid-
ney. Detailed studies of certain rare forms of nephritis have
provided evidence that complement activation can directly cause
tissue injury. Appreciation of the importance of complement in
hyperacute rejection of xenotransplants has given new impetus to
the development of complement inhibitors. A narrative review is
provided, with a brief overview of the complement pathway and its
regulatory mechanisms, mechanisms of complement-induced tis-
sue injury, local complement production, and the renal conse-
quences of complement dysregulation. Currently available forms
of therapy aimed at the complement system are reviewed, and
possible future therapeutic strategies are suggested. The comple-
ment system plays a direct causal role in tissue injury in certain
forms of renal disease. Specific forms of therapy are becoming
available that can selectively interrupt complement activation or
promote its regulation. Much of the drive for the development of
these therapies comes from the field of xenotransplantation, but
these forms of therapy should also be tested in various primary
renal diseases.
The complement pathway is a phylogenetically ancient
system of interacting proteins that forms part of the host
defence response. Complement has been of interest to
nephrologists and renal pathologists ever since techniques
of immunohistological analysis allowed the demonstration
of complement components deposited in the kidney in
certain forms of glomerulonephritis, associated in some
cases with evidence of systemic complement activation.
However, whether such evidence of local or systemic
complement activation is causally related to tissue injury in
the kidney, or merely an epiphenomenon, has remained
controversial. This argument remained only of academic
rather than clinical significance while there were no specific
methods of achieving selective blockade of complement
activation. Several recent advances have suggested that this
is an area that deserves further attention from those
interested in the pathogenesis and treatment of kidney
disease. First, it has become apparent that complement is
not only involved in the lysis of target cells. There are many
more subtle effects on cell biology that can result from
sublytic complement attack or as a response to the by-
products of complement activation. Second, there has been
an increasing appreciation that complement components
are produced locally in a variety of tissues, and that this is
particularly prominent in the kidney. Third, detailed stud-
ies of certain rare forms of nephritis have indicated that
complement activation may play a direct causal role in
tissue injury. Fourth, and perhaps most significant, is the
recent development of novel therapeutic approaches aimed
at preventing or limiting complement activation systemi-
cally or locally. The purpose of this article is to review some
of these recent advances and attempt to assess their
significance for nephrology.
THE COMPLEMENT PATHWAY
Over thirty proteins are involved in the three pathways of
complement activation (Fig. 1), and many of these, some
cell-bound and some secreted, have regulatory functions
that impose tight control on complement activation. This
complex regulatory machinery prevents unnecessary or
excessive complement activation in health. The classical
pathway is mainly activated by antigen/antibody complexes.
This is the pathway responsible for the augmentation of the
effector functions of antibodies and also is concerned with
the effective handling of immune complexes by mainte-
nance of their solubility, allowing their delivery to the
reticulo-endothelial system for safe disposal. The alterna-
tive pathway is more concerned with host defence, being
mainly activated by foreign surfaces such as microorgan-
isms. It has two distinguishing features: activation is anti-
body-independent, and the pathway has a constant low-
level of activation, existing in a state of so-called “tickover.”
Therefore, regulation is critical to prevent excessive activ-
ity, and an understanding of this regulatory mechanism is
crucial to the explanation of the dysregulated alternative
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pathway activation associated with some forms of renal
disease, to be considered later. Regulatory mechanisms
exist in the fluid phase and on the cell membrane, and these
two groups of inhibitors work together to downregulate
inappropriate complement activation. The rate-limiting
enzyme is the alternative pathway C3 convertase, denoted
C3bBb. This enzyme is unstable, having a half-life of only a
few minutes in vivo. Its dissociation is promoted in the fluid
phase by two regulatory proteins factor H and factor I, and
on the cell membrane by decay accelerating factor (DAF).
A recently described third pathway of complement activa-
tion is the lectin or mannan-binding protein pathway [1],
which has similar consequences to those of classical path-
way activation. The relevance of this pathway to renal
disease is not yet known.
MECHANISMS OF COMPLEMENT-INDUCED
INJURY
Activation of either the classical or alternative pathway
leads to a final common pathway of complement activation,
the terminal pathway. This culminates in the formation of
the membrane attack complex (MAC or C5b-9), which
when inserted in sufficient quantity into the plasma mem-
brane of target cells leads to the formation of pores, entry
of water and extracellular ions, cell swelling, and ultimately
cell lysis. It has become apparent in recent years that C5b-9
also has other potent effects on the biology of target cells,
and that sublytic complement activation may be an impor-
tant phenomenon in vivo. Much of the work on this subject
relates to endothelial cells, but other intrinsic renal cells
such as mesangial cells or podocytes may be affected in a
similar way. Production of C5b-9 on the endothelial cell
surface has procoagulant and pro-inflammatory conse-
quences, leading to rapid influx of calcium into the cell,
secretion of Weibel-Palade bodies with release of proco-
agulant high molecular weight forms of von Willebrand
factor, exposure of binding sites for factor Va, release of
platelet activating factor that stimulates the adhesion and
aggregation of platelets, and upregulation of the expression
of GMP-140, a p-selectin that promotes the adherence of
neutrophils [2]. By-products of complement activation may
further amplify the process. For example, C3a and C5a,
by-products respectively of cleavage of C3 and C5 (by
either pathway), act as anaphylatoxins that attract and
Fig. 1. Overview of the complement system showing the three pathways (classical, alternative and lectin) that converge on a common terminal
pathway.
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activate leukocytes, recruiting them to the inflammatory
focus. C5a also leads to the release of procoagulant hepa-
ran sulphate from endothelial cells [3]; deposition of iC3b,
a ligand for the complement receptor CR3 on neutrophils,
on the endothelial cell surface will further promote the
accumulation of inflammatory leukocytes [4]. Complement
activation also has effects on platelets, with calcium-depen-
dent activation of protein kinases leading to secretion of
procoagulant molecules from storage granules [5]. Thus,
the net result of complement activation on platelet-endo-
thelial interactions is a shift towards a more procoagulant
state. Sublytic C5b-9 also has potent pro-inflammatory
effects on mesangial cells in vitro [6, 7]. The recent dem-
onstration that human mesangial cells have receptors for
the anaphylatoxin C5a, and that binding of C5a to mesan-
gial cells induces upregulation of transcription factors and
early response genes [8], illustrates a novel mechanism
whereby complement activation may directly influence res-
ident cells in the kidney, in addition to the pro-inflamma-
tory effects mediated via leukocyte attraction.
It has been known for many years that complement
influences the afferent arm of an immune response. Com-
plement-depleted mice are less able to mount an antibody
response [9]. A mechanism for this is illustrated by recent
work showing that C3d, a breakdown product of C3 and the
ligand for complement receptor CR2, can act as an adju-
vant: antigen tagged with C3d molecules was much more
potent at eliciting an antibody response, presumably due to
cross-linking of CR2 molecules on B lymphocytes [10].
LOCAL COMPLEMENT PRODUCTION
Most complement components are produced in the liver,
but local production in a number of organs is now well
documented [11]. In the kidney this has been most clearly
shown for C3 and C4, which are synthesized and secreted
by renal tubular epithelial cells, mesangial cells and glo-
merular epithelial cells [12]. This expression is upregulated
by pro-inflammatory cytokines, and also in various forms of
nephritis. Factor B is expressed in normal kidney, and
possibly also factor D [13, 14]. Complement regulatory
molecules including decay accelerating factor (DAF,
CD55) and membrane cofactor protein (MCP, CD46) are
expressed in the kidney in health and disease [15, 16].
Another tissue capable of local production of complement
components is the vascular endothelium. Endothelial cells
lie at the interface between the tissues and the circulation,
and complement activation on the endothelial surface is a
common feature in many forms of tissue injury. As with
other tissues, the relative contributions of locally produced
complement and circulating complement remain to be
determined. Certainly the local expression of regulators of
complement activation makes teleological sense, since
there may be a need to control complement activation at
this site. Endothelial cells abundantly express membrane-
bound regulators of complement activation such as CD59,
MCP and DAF, and this underlies the strategy for preven-
tion of hyperacute xenograft rejection by transgenic expres-
sion of the human versions of these regulators in pigs
[reviewed in 17]. Factor H, important in regulation of the
alternative pathway, is also expressed by endothelial cells.
Intriguingly, pro-inflammatory cytokines (which enhance
endothelial synthesis of C3 and factor B) lead to downregu-
lation of factor H, tipping the balance in favor of activation,
presumably as a defence mechanism [18]. Hemolytic-ure-
mic syndrome (HUS) is characterized by marked endothe-
lial injury, especially in the kidney, and it is therefore
fascinating that defective complement regulation may pre-
dispose to this condition. This is considered further in the
next section.
RENAL CONSEQUENCES OF COMPLEMENT
DYSREGULATION
As mentioned earlier, tight regulatory mechanisms exist
to limit complement activation in health. For the alterna-
tive pathway, factor H is a key regulatory protein, and the
consequences of loss of its regulatory effects are amply
illustrated by study of individuals whose ability to produce
this protein is deficient. This has been best studied in a
variety of Yorkshire pig [19], but rare human cases have
also been reported [20]. In the pig, genetic factor H
deficiency leads to the development of glomerulonephritis
(GN), with morphological appearances directly analogous
to mesangiocapillary GN type II in humans (also known as
membranoproliferative GN type II or dense deposit dis-
ease), which leads to the rapid development of renal failure
and death from uremia [19]. The pigs have evidence of
unregulated systemic alternative pathway activation, and
importantly it has recently been shown that administration
of exogenous factor H is an effective therapy, even if
treatment is not started until after GN is established [21].
These animals prove that alternative pathway dysregulation
alone can cause nephritis, and that restoration of the
capacity to regulate the alternative pathway is sufficient to
restore health. In humans, genetic factor H deficiency may
also lead to MCGN [20], and the molecular basis of the
defect has recently been characterized in one such patient.
Mutations leading to loss of cysteine residues altered the
protein structure in such a way that intracellular processing
of factor H was disrupted [22]. The importance of func-
tional factor H is further illustrated by a case report of an
individual whose serum contained a monoclonal lambda
light chain that interacted with factor H in vitro and
prevented its action, allowing unregulated alternative path-
way activation. That patient also developed type II MCGN
[23]. Thus, disruption of the action of factor H by whatever
mechanism can lead to MCGN. Another area of recent
research should be mentioned that concerns HUS, a con-
dition of great interest to nephrologists. One early report
indicated that factor H deficiency might predispose to HUS
[24], and certainly complement activation is conspicuous in
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this condition [25]. Rarely, recurrent HUS occurs in a
familial form, and it has recently been reported that
mutations of the factor H gene in these families are
associated with unregulated complement activation and
episodic HUS [26]. The relevance of this to more common
forms of HUS is not yet certain, but it is noteworthy that an
abnormality of the factor H gene has been found in at least
one individual with sporadic HUS [26] and that the factor
H gene is polymorphic [27, 28], leading to the possibility
that genetic variability at this locus could be associated with
susceptibility to disease.
Another situation in humans where unregulated alterna-
tive pathway activation is associated with MCGN is in the
presence of nephritic factor (NeF), an IgG autoantibody
that binds to a neoantigen formed when the alternative
pathway C3 convertase enzyme, C3bBb, is assembled. The
antibody stabilizes this enzyme and protects it from degra-
dation by factor H. Thus, the half-life of the enzyme is
prolonged and the normal regulatory mechanism is sub-
verted. The close association between NeF and MCGN
implies, but does not prove, causality [29]. However, the
fact that similar renal injury arises when the alternative
pathway is dysregulated by the other mechanisms outlined
above, namely factor H deficiency or dysfunction, strongly
implies that it is the complement activation per se which
induces the nephritis. The other clinical condition associ-
ated with NeF, with or without coexisting nephritis, is
partial lipodystrophy (PLD) in which there is loss of
adipose tissue from the face, arms and upper trunk [30].
Adipocytes are another abundant source of local comple-
ment production, particularly of factor D, which plays a
central role in normal adipose tissue regulation [reviewed
in 31]. We have reported that NeF-containing serum or
IgG, but not normal or disease-control sera/IgG, could
induce complement-dependent lysis of adipocytes in vitro
[32, 33]. Furthermore, there are regional variations in levels
of expression of factor D that mirror the distribution of fat
cell loss in PLD, the higher levels being found in fat from
the face and upper trunk [33]. Thus, NeF appears capable
of directly causing adipocyte destruction, and the level of
production of factor D by adipocytes may determine their
susceptibility to injury by NeF. Since intrinsic renal cells
express an array of complement proteins similar to those
expressed by adipocytes, the obvious implication is that
NeF may directly injure renal cells in an analogous manner.
As yet there is no direct evidence for this action, but a
recent report showed that alternative pathway activation
can injure renal tubular epithelial cells [34]. Lupus nephri-
tis is the archetypal immune complex nephritis, where
complement activation in the glomerulus is assumed to be
important, and therapy aimed at complement has been
advocated. Intriguingly, a very recent report in a murine
model of lupus strongly suggests that Fc receptor-mediated
mechanisms of inflammation are more important that those
involving complement [35]. The importance of complement
in renal disease is not, however, confined to rare esoteric
forms of glomerulonephritis as complement activation may
play an important role in other, more common forms of
renal injury. For example, there is a wealth of evidence for
a vital role of complement in ischemia-reperfusion injury.
This is important to nephrologists in the context of trans-
plantation, after revascularization for renovascular disease,
and possibly also in some forms of ischemic acute renal
failure. Complement inhibition provides substantial protec-
tion against this form of injury [36–38], probably by inhib-
iting leukocyte attraction and infiltration [38]. Another
important and possibly underestimated cause of renal
injury is embolization of material from atheromatous
plaques [39]. One feature of the syndrome associated with
cholesterol emboli is systemic complement activation lead-
ing to hypocomplementemia [40], and it has been shown
that components of atheroma are potent activators of
complement [41, 42]. The therapeutic potential of comple-
ment inhibition in patients suspected of having this form of
renal injury may be considerable but as yet remain unex-
plored. Indeed, complement may be involved in atheroscle-
rosis itself. The inflammatory nature of atherosclerotic
vascular disease is increasingly being appreciated. In one
experimental model, deposition of C5b-9 was one of the
earliest histological manifestations, preceding monocyte
infiltration and foam cell development [43], indicating that
the terminal complement pathway is likely to be involved in
atheroma development and that measures aimed at com-
plement inhibition may have therapeutic potential in ath-
erosclerosis. There may be implications for the role of
complement in chronic allograft rejection, elements of
which have similarities to atherosclerosis [44]. Another
example of the role of the complement system in microvas-
cular injury in vivo is illustrated by experiments examining
renal injury in mice rendered hypertensive by uninephrec-
tomy and treatment with desoxycorticosterone. Mice with
C5 deficiency, unable to assemble C5b-9 after proximal
complement activation, showed a dramatic reduction in
glomerular damage compared to congenic mice with an
intact terminal complement pathway [45].
THERAPY AIMED AT COMPLEMENT
Current anti-inflammatory and immunosuppressive
treatments are nonspecific. It is quite possible that cortico-
steroids, for example, exert some of their effects by inter-
ference with complement-mediated injury. As we aim for
more selective forms of intervention, the precise identifi-
cation of targets will become ever more important. Appre-
ciation of the role of complement in renal injury has
accumulated over the years, but only recently have specific
methods of complement blockade become available.
It is beyond the scope of this article to consider the
strategies being used to overcome complement activation
in xenograft rejection, or indeed in transplantation in
general. These have been recently reviewed elsewhere [17]
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and will only be considered here when they shed light on
possible therapeutic approaches for native renal disease.
Until recent years, studies of the role of complement in
tissue injury have relied on rare genetic variants where
individual complement components are deficient, or on
crude methods of complement depletion such as the use of
cobra venom factor. “Accidents of nature” with comple-
ment deficiency have given useful information about the
importance of complement in induction of tissue injury.
For example, in an experimental model of membranous
GN induced in rabbits with cationized bovine serum albu-
min, C6 deficient rabbits showed glomerular morphology
and deposits of immunoglobulin and C3 that were identical
to those seen in normal rabbits, but the C6 deficient
animals did not develop proteinuria [46]. This may give
hints about useful therapeutic targets for human membra-
nous GN, that is, selective interference with C5b-9 may be
possible with monoclonal antibodies to individual compo-
nents. This therapeutic strategy has already been shown to
be successful in passive Heymann nephritis in the rat [47]
and in a murine model of lupus [48]. As yet there is no
experience with this form of therapy in human disease.
Studies of complement-deficient individuals have also illus-
trated potential hazards of therapy with individual comple-
ment components. For example, in C3 deficient dogs
(which develop MCGN) treatment with exogenous C3 in
the form of normal dog serum was associated with a
worsening of the nephritis [49]. Similarly, C6-deficient
humans, who are at increased risk of Neisserial infections,
may be actively harmed by plasma therapy due to enhanced
complement activation when an intact pathway is restored
by provision of a fresh supply of the missing protein [50].
With the advent of gene knockout technology, further
genetic mutants are available to address the role of indi-
vidual complement components [51], and these animals will
provide a useful resource for experimental studies, helping
to elucidate the relative importance of each pathway of
complement activation in health and disease. One particu-
larly striking example is the recent report that mice with
targeted disruption of the C1q gene, which are completely
deficient in C1q and therefore unable to achieve any
activation of the classical complement pathway, develop a
lupus-like nephritis [52]. This in itself may not be particu-
larly surprising since C1q deficiency in humans is associated
with severe lupus [53]. However, the intriguing observation
in the C1q knockout mice was the associated increase in
apoptotic bodies in their glomeruli, irrespective of the
severity of glomerulonephritis [52]. This implies that C1q,
and hence the classical complement pathway, plays a role in
the normal clearance of apoptotic cells from the glomeru-
lus; a similar pathway has recently been proposed for the
clearance of apoptotic keratinocytes [54]. The provocative
interpretation of these results is that, since the typical
autoantigens in lupus are nuclear or cytoplasmic compo-
nents that are normally sequestered intracellularly and
therefore not accessible to the immune system, C1q defi-
ciency may predispose to autoimmunity by allowing persis-
tence of apoptotic cells that display autoantigens on their
surface [52, 54]. Enhancement of clearance of apoptotic
cells by promotion of this function of the classical pathway
could provide a novel therapeutic strategy for lupus or
other autoimmune nephritides.
One major problem with cobra venom factor (CVF) is
that in order to bring about complement depletion, it first
causes massive complement activation. Thus, any beneficial
effects of complement depletion may be masked by the
results of this initial activation phase [55]. Furthermore,
CVF is highly immunogenic, leading to the generation of a
neutralizing antibody response so that CVF therapy be-
comes ineffective within 5 to 10 days. Efforts are being
made to produce less immunogenic variants that retain
decomplementing activity.
In designing therapies to regulate complement activa-
tion, it seems logical to exploit the fact that the complement
system includes a number of naturally-occurring regulators.
One example was alluded to earlier, that is, administration
of purified factor H to animals in which this protein was
deficient led to correction of their complement regulatory
defect [21]. Whether there would be any value in adminis-
tration of supraphysiological doses of factor H to individ-
uals who are not factor H deificent, but have excessive
alternative pathway complement activation for some other
reason, remains unknown. Another naturally occurring
complement regulator is complement receptor type 1 or
CR1 (also known as CD35) [56]. This is a membrane-bound
molecule that binds C3b and C4b and is normally expressed
on erythrocytes, myelomonocytic cells, B lymphocytes,
some T lymphocytes, and on glomerular epithelial cells.
CR1 dissociates both classical and alternative pathway C3
convertases, and is therefore a potent inhibitor of comple-
ment activation via both pathways. There is a naturally
occurring soluble form (soluble CR1, sCR1) that is present
in tiny concentrations in plasma [57]. The role of this
molecule in normal regulation of complement in the fluid
phase in vivo is unknown, but its potency as a complement
inhibitor made this a logical choice for development as a
therapeutic agent. Recombinant sCR1 is now available and
has been shown to have potent effects on tissue injury in
models of ischemia-reperfusion [36–38], xenotransplanta-
tion [58, 59] and allotransplantation [60]. There is evidence
from one xenograft model that an agent inhibiting neutro-
phil adhesion to endothelium by preventing up-regulation
of the CD11b/CD18 adhesion molecule has synergistic
effects with sCR1 [61], illustrating the point that comple-
ment inhibition may only form one component of novel
therapeutic approaches. Promising results with sCR1 have
been reported in three experimental models of renal dis-
ease: passive Heymann nephritis, antithymocyte serum-
induced mesangial proliferative GN, and concanavalin A-
induced diffuse proliferative GN [62]. Each of these models
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is known to be complement-dependent, and in each case
sCR1 reduced proteinuria and improved indices of glomer-
ular inflammation. However, very large doses of sCR1 were
used (60 mg/kg/day), and the logistic and economic impli-
cations of therapy at similar dosages would be considerable
for human therapy. Furthermore, the relevance of these
observations to human GN is limited by the fact that the
effects were seen with sCR1 pre-treatment, that is, before
the induction of disease. It remains to be seen whether
similar benefits are seen when treatment is delayed until
after disease has become established, more closely resem-
bling the clinical situation.
There is a brief report of the effectiveness of a compound
called nafamostat mesilate on immune complex GN in
humans (3 patients with lupus nephritis and 2 with cryo-
globulinemia), together with the claim that this serine
protease inhibitor exerts its effects by blockade of classical
pathway complement activation [63]. There are many other
possible explanations of the reduction of proteinuria re-
ported with this agent, and these results await confirmation.
Nevertheless, the general principle that therapy aimed at
the complement system can have useful benefits is sup-
ported by this kind of clinical experiment. A semisynthetic
polysaccharide called pentosan polysulfate, a potent inhib-
itor of complement activation in vivo, has recently been
shown to have useful effects in a rabbit model of ischemia-
reperfusion injury [64]. This agent has not yet been tested
in any models of nephritis or in human disease.
FUTURE APPROACHES
Administration of other exogenous complement inhibi-
tors has been studied recently, mainly in the context of
xenotransplantation. Of particular interest are those mole-
cules, including CD59 and DAF, which are linked to the
cell membrane via a glycosylphosphatidylinositol (GPI)
anchor. A valuable property of such molecules is that when
present in a soluble form they can reinsert into cell
membranes, raising the possibility that infused proteins
could become incorporated into the membranes of target
cells. Porcine endothelial cells can be protected from lysis
by human serum by the administration of exogenous CD59
or DAF [65]. Thus, it would be theoretically possible to
protect an organ from complement-mediated attack by
infusing complement regulators locally. The usefulness of
such an approach may be limited by the fact that serum
lipoproteins inhibit the incorporation of GPI anchors into
cell membranes [66], and also because rapid membrane
turnover would mean that treatment would need to be
repeated at frequent intervals. The problems of exogenous
administration of complement regulators would be avoided
if transgenic technology could be used to allow local
expression of these molecules at the site of injury. Again,
this approach so far mainly been proposed for xenotrans-
plants, but there is no reason why similar techniques could
not be exploited in native organs. In vitro, transfection of a
complement regulator provides potent protection to mes-
angial cells against complement-mediated injury, either
lytic or sublytic [67]. The main limitations to such gene
therapy approaches at present concern the lack of suitable
vectors for delivery of genes to the target organs or cells in
vivo.
As mentioned earlier, individual complement compo-
nents can be targeted specifically, for example, by mono-
clonal antibodies that block their activity. Prevention of the
assembly of C5b-9 seems most likely to have therapeutic
value, and using anti-C6 antibodies in this way is beneficial
in passive Heymann nephritis in the rat [47]. However, the
importance of C5b-9 in the active form of this condition,
which more closely mimics human membranous GN, is
disputed [68] and it is therefore not certain that a similar
approach would be useful in the analogous human condi-
tion. It may also be worth testing this type of therapy in
other forms of GN. There is some evidence for the role of
C5b-9 in mesangial proliferative GN [69] and in murine
lupus [48]. The C5a receptor on leukocytes is a powerful
mediator of inflammation because the blockade of this
molecule by antibodies or by specific antagonists has pow-
erful effects on leukocyte recruitment and activation. One
potent group of C5a receptor antagonists, generated by
modification of the C terminus of C5a, has recently been
reported [70], and these agents showed potent inhibitory
effects on neutrophil chemotaxis, adherence and activation
in vitro together with promising anti-inflammatory effects in
vivo in rabbits and pigs. This type of anti-inflammatory
therapy could have very wide applicability in human dis-
ease.
CONCLUSIONS
Complement plays a role in diverse forms of renal injury.
Modern molecular biological techniques have opened new
possibilities for selective immunotherapy, and interference
with complement activation is no exception. In particular,
the recognition of the importance of complement in hyper-
acute xenograft rejection has led to a resurgence of interest
in the development of complement inhibitors. These ad-
vances may benefit patients with various forms of primary
renal disease, possibly contributing to the field of transplan-
tation in an unforeseen way: better treatment of primary
renal disease leads to a reduced need for renal replace-
ment!
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